SurModics — Investor Presentation (November 2011)
36 slides from SurModics's investor presentation, Nov 29, 2011
Slide 1: Investor Presentation
Investor Presentation Gary Maharaj President and CEO November 2011 SurModics Bringing Innovation Together
Slide 2: Safe Harbor Statement and Use of Non-GAAP Financials
Safe Harbor Statement and Use of Non-GAAP Financials Some of the statements made during this meeting may be considered forward-looking statements. The 10-K for fiscal year 2011 identifies certain factors that could cause the Company’s actual results to differ materially from those projected in any f
Slide 3: SurModics: Company Snapshot
SurModics: Company Snapshot NASDAQ: SRDX Market Cap: $209M Cash**: $93M Debt: $0 Enterprise Value: $116M Revenue*: $52.7M Operating Cash Flow*: $22.9M Earnings*: $10.8M Improving Lives By Enabling the Detection and Treatment of Disease Medical Device Gold standard, market leading lubricious coatings
Slide 4: Where We Are Today
Where We Are Today Refocused on our core businesses •Core businesses have a pedigree of consistently outperforming the market •Commitment to R&D activities provides our Medical Device and IVD businesses with the potential for meaningful, differentiated products Leading market positions aided by diff
Slide 5: Focus on the Core Business
Focus on the Core Business Tightly Defined Core Businesses •Generates the majority of the revenue for the business •Leverages existing strategic assets such as people, technology, expertise and customer base •Generates growth for the business with the highest probability at the lowest level of risk
Slide 6: Business Overview
FSurModics Bringing Innovation Together™ se a Me. } = - Business Overview
Slide 7: Medical Device – Overview
Medical Device – Overview Minimally invasive procedures often utilize SurModics coated catheters and guidewires to treat cardiovascular, peripheral and neurovascular diseases Every minute of every day, around the globe, there is a minimally invasive procedure performed utilizing SurModics hydrophili
Slide 8: Medical Device Value Proposition
Medical Device Value Proposition 8 Long access paths Challenging therapy sites Brain vessels Coronary arteries Long access paths and tortuous anatomy underscore the need for lubricious coatings to ensure successful delivery of medical devices.
Slide 9: Medical Device - Proven Track Record
Medical Device - Proven Track Record Oncology Microcatheters and Guidewires Cardiovascular Coronary stent systems Specialty guidewires Chronic total occlusion device Angioplasty catheters Percutaneous heart valves Access systems Defect repair delivery systems Neurological Infusion catheters Hydrocep
Slide 10: Medical Device – Strong Performance
Medical Device – Strong Performance Hydrophilic coatings represent 85% of Medical Device revenue 50% Medical Device Operating Margin 8% Year-to-Year Hydrophilic Revenue Growth Hydrophilic Coating Revenue $5M $6M $7M $8M $9M 1Q'10 2Q'10 3Q'10 4Q'10 1Q'11 2Q'11 3Q'11 4Q'11 $10M 10
Slide 11: Medical Device – Growth Drivers
Plus a Bright Future… •New hydrophilic coating platform available in 2012 •Opportunities for market expansion •Opportunities for new platform breakthroughs •Well positioned in growing market segments Medical Device – Growth Drivers © 2011 SurModics, Inc. 12 Medical 11
Slide 12: Medical Device – Bright Future: Next generation hydrophilic coating platform
Medical Device – Bright Future Next generation hydrophilic coating platform •Offers compelling value proposition –Preserves our gold standard lubricity and durability performance –Performance that meets increased regulatory requirements –Leverages our customers existing manufacturing process 12
Slide 13: Medical Device – Bright Future: New platform breakthroughs
Medical Device – Bright Future Opportunities for new platform breakthroughs •New drug coated balloon technology •Drug delivery control is an important advantage to drive adoption –More drug stays on the balloon during transit to lesion site –Increased drug transfer to disease site from balloon –Enha
Slide 14: Medical Device – Market Opportunities
Medical Device – Market Opportunities SRDX est 75% of industry market share •Strong competitive advantages •Barriers to entry •8% SRDX growth vs 5% rest of Industry Opportunities for Market Expansion Opportunity to penetrate in-house coatings •Increased regulatory requests regarding coating performa
Slide 15: Medical Device – Market Opportunities: Growing segments
Medical Device – Market Opportunities Well positioned in growing market segments… Neurovascular –$1.0B neurovascular market growing at 9% –$3.0B U.S. ischemic stroke market opportunity Percutaneous valve therapy –$3.0B transcatheter aortic valve implantation market opportunity Peripheral vascular –$
Slide 16: Medical Device -- Competitive Advantages
Medical Device -- Competitive Advantages 1.Gold standard performance Superior lubricity provides ease-of-use benefit with customers’ devices 2.Speed-to-market In-house regulatory support and Device Master Files have assisted our customers in gaining worldwide regulatory approval for over 100 devices
Slide 17: In Vitro Diagnostics - Overview
In Vitro Diagnostics - Overview Over half of the top 10 global In Vitro Diagnostic companies are our customers Food allergy tests (membrane format) Infectious disease tests (lateral flow format) Every second of every day 8 diagnostic tests are performed utilizing SurModics’ products Autoimmune disea
Slide 18: In Vitro Diagnostics – Strong Performance
In Vitro Diagnostics – Strong Performance 17% Year-to-Year IVD Revenue Growth 33% IVD Operating Margin In Vitro Diagnostics (IVD) represents 25% of SurModics revenue FY 2011: $13.2M FY 2010: $11.2M IVD Revenue In Vitro Diagnostic Revenue 0 $1M $2M $3M $4M 1Q'10 2Q'10 3Q'10 4Q'10 1Q'11 2Q'11 3Q'11 4Q
Slide 19: In Vitro Diagnostics – Growth Drivers
In Vitro Diagnostics – Growth Drivers Plus a Bright Future… •New products that support customer needs •A growing customer base •Opportunity to increase our “share of test” 19
Slide 20: In Vitro Diagnostic – Product Opportunities
In Vitro Diagnostic – Product Opportunities New Products •Provide opportunities to increase our “share of test”; capture new customers; penetrate new market segments •Enhance our pipeline of new IVD products •Launched two new core diagnostic products in the fourth quarter of FY2011 •More to come, pl
Slide 21: SurModics Assay Diluent
In Vitro Diagnostic – Product Opportunities New Products SurModics Assay Diluent (July 2011) •Description •A solution used to dilute patient sample (e.g., blood) in a diagnostic test •Value Proposition –Reduces the number of false-positives without sacrificing test sensitivity –Best-in-class perform
Slide 22: BioFX TMB Enhanced HRP Membrane Substrate
In Vitro Diagnostic – Product Opportunities New Products BioFX TMB Enhanced HRP Membrane Substrate (Sep. 2011) •Description –A solution that changes color when disease is present in a diagnostic test. For use with membrane formats •Value Proposition –Potential to reduce number of steps to get to dis
Slide 23: Growing customer base
© 2011 SurModics, Inc. 23 Growing customer base •42% increase in the number of diagnostic test kit customers since 2009 •Many customers launch one or more new diagnostic test kits annually •Once we are a supplier to a customer, our products are often sourced into new customer diagnostic tests In Vit
Slide 24: In Vitro Diagnostic – Growth Opportunities: share of test
© 2011 SurModics, Inc. 24 In Vitro Diagnostic – Growth Opportunities Increase our “share of test” • A typical diagnostic test uses 4 to 6 chemical component products •Sales and marketing activities provide opportunities to cross-sell and increase our “share of test” •New product offerings can also i
Slide 25: In Vitro Diagnostic - Competitive Advantages
© 2011 SurModics, Inc. 25 In Vitro Diagnostic - Competitive Advantages 1.Strong core competencies and chemistry expertise SRDX chemistry expertise has assisted our customers in developing difficult diagnostic tests and has led to meaningful new products 2.Gold standard performance Papers in several
Slide 26: Financial Review
Financial Review Tim Arens, Vice President of Finance and Interim CFO 26
Slide 27: Key Operating Metrics Non-GAAP Continuing Operations
© 2011 SurModics, Inc. 27 FY 2011FY 201037%Continuing Opsex-PharmaceuticalsProduct Gross MarginR&D as % of Revenue66%61%28%35%SG&A as % of RevenueOperating MarginEBITDA Margin28%31%23%30%23%Key Operating Metrics Non-GAAP Continuing Operations
Slide 28: Non-GAAP Continuing Operations Results
© 2011 SurModics, Inc. 28 (000's)FY 2011FY 2010ChangeRevenue: Royalties and License Fees$30,386$33,844-10% Product Sales20,15017,36416% Research & Development2,1913,198-31%Total Revenue52,72754,406-3%Cost of Goods Sold6,7516,805-1%Operating Expenses29,54131,398-6%Operating Income16,43516,2031%Invest
Slide 29: Non-GAAP Results excluding Cypher
© 2011 SurModics, Inc. 29 (000's)FY 2011FY 2010ChangeRevenue: Medical Device1$32,909$33,394-1% In Vitro Diagnostics13,15011,19417%Total Revenue46,05944,5883%Operating Income10,1636,94846%Net Income$6,937$5,13735%EPS$0.40$0.3035%Non-GAAP Continuing Operations Results (excludes Cypher, Pharmaceuticals
Slide 30: Medical Device Revenue Performance
© 2011 SurModics, Inc. 30 Medical Device Revenue Performance Medical Devices Hydrophilic Coatings 1Q ‘09 2Q ‘09 3Q ‘09 4Q ‘09 1Q ‘10 2Q ‘10 3Q ‘10 4Q ‘10 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 Non-Cypher Device DD Revenue FY 2011: $0.5M FY 2010: $4.0M Device Drug Delivery $12M $10M $8M $6M $4M $2M $0
Slide 31: Segment Operating Income Performance
© 2011 SurModics, Inc. 31 Segment Operating Income Performance $0$1$2$3$4$5$6$7$81Q'102Q'103Q'104Q'101Q'112Q'113Q'114Q'11Non-GAAP Operating IncomeMedical DeviceIVDin millions 4Q’10 GAAP results include an asset impairment charge of $0.4M in the Medical Device segment.
Slide 32: Revenue and EPS Guidance FY2012
© 2011 SurModics, Inc. 32 $44.6M $46.1M $47 - $51M $0.30 $0.40 $0.45 - $0.53 Long-term Goal: Double-digit revenue & EPS growth 2% - 11% FY 2012 growth rate 3% FY 2011 growth rate 13% - 33% FY 2012 growth rate 35% FY 2011 growth rate Revenue from Continuing Operations (ex-Cypher and Pharmaceuticals)*
Slide 33: Investor Relations Contact
© 2011 SurModics, Inc. 33 Investor Relations Contact For additional inquiries, please contact: Tim Arens 952-500-7056
Slide 34: Appendix
FSurModics Bringing Innovation Together™ Appendix
Slide 35: FY2011 Non-GAAP Continuing Operations Results
© 2011 SurModics, Inc. 35 FY2011 Non-GAAP Continuing Operations Results (excludes Pharmaceuticals and one-time charges) As Reported GAAP1Adjustments2Adjusted Non-GAAPRevenueRoyalties and license fees30,583$ (197)$ 30,386$ Product sales22,965(2,815)20,150$ Research and development14,233(12,042)2,191$
Slide 36: FY2010 Non-GAAP Continuing Operations Results
© 2011 SurModics, Inc. 36 FY2010 Non-GAAP Continuing Operations Results (excludes Pharmaceuticals and one-time charges) 2 Adjustments reflect exclusion of Pharmaceuticals operating results and certain other non-recurring or event-specific items recognized in the period in accordance with GAAP.1 Incl